Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

REBECCA JONES

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1104260819
CMS profile
593769
Location
PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$18,476.30

244 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 244 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

REBECCA JONES

NPI 1104260819 · CMS profile ID 593769

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 244 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1104260819?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
REBECCA JONES, NPI 1104260819, CMS profile ID 593769. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 244 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1104260819?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). REBECCA JONES, NPI 1104260819, CMS profile ID 593769. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 244 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1104260819?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
REBECCA JONES, NPI 1104260819, CMS profile ID 593769, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 244 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1104260819?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

244 matching records · $18,476.30 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 244 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 244.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
TG Therapeutics, Inc. $12.5008/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136872071 CMS
Biogen, Inc. $13.8408/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104863414 CMS
Biogen, Inc. $2.8208/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104838686 CMS
PFIZER INC. $16.2908/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131784404 CMS
Ipsen Biopharmaceuticals, Inc $23.9308/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091968221 CMS
ABBVIE INC. $11.0808/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104009200 CMS
Celgene Corporation $21.7608/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101164328 CMS
ABBVIE INC. $33.4407/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104009198 CMS
TG Therapeutics, Inc. $23.0007/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136872099 CMS
Celgene Corporation $18.0707/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101164326 CMS
Eisai Inc. $18.3107/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110775651 CMS
BANNER LIFE SCIENCES, LLC $7.0507/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147030677 CMS
BANNER LIFE SCIENCES, LLC $9.2507/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147030679 CMS
Lilly USA, LLC $16.6007/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135332854 CMS
ABBVIE INC. $6.2907/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104009196 CMS
BANNER LIFE SCIENCES, LLC $17.1407/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147030593 CMS
EMD Serono, Inc. $25.6807/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120215342 CMS
Neurocrine Biosciences, Inc. $33.4607/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150820646 CMS
UCB, Inc. $21.0507/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143065875 CMS
Novartis Pharmaceuticals Corporation $20.7707/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087020450 CMS
Teva Pharmaceuticals USA, Inc. $14.1707/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151612096 CMS
Neurocrine Biosciences, Inc. $37.9807/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150816270 CMS
ARGENX US, INC. $34.8807/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142113907 CMS
BANNER LIFE SCIENCES, LLC $6.4307/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147030411 CMS
BANNER LIFE SCIENCES, LLC $11.7407/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147030413 CMS
Alexion Pharmaceuticals, Inc. $26.5706/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1094012713 CMS
ARGENX US, INC. $24.5906/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142108271 CMS
Eisai Inc. $20.1706/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110775647 CMS
ABBVIE INC. $27.2806/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104009194 CMS
PFIZER INC. $14.2906/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131502216 CMS
PFIZER INC. $1.5506/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131722500 CMS
ACADIA Pharmaceuticals Inc $25.0106/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147978098 CMS
Celgene Corporation $16.6406/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101164324 CMS
ABBVIE INC. $30.2306/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104009192 CMS
PFIZER INC. $14.1706/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131459996 CMS
Biogen, Inc. $17.7206/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104843894 CMS
Novartis Pharmaceuticals Corporation $25.1406/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087020442 CMS
Genentech USA, Inc. $34.2406/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133094465 CMS
BANNER LIFE SCIENCES, LLC $12.4206/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147030097 CMS
TG Therapeutics, Inc. $20.8106/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136872027 CMS
BANNER LIFE SCIENCES, LLC $20.4806/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147030067 CMS
BANNER LIFE SCIENCES, LLC $4.4606/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147030049 CMS
ABBVIE INC. $33.1106/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104009190 CMS
ABBVIE INC. $24.7706/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104009186 CMS
ABBVIE INC. $125.0006/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104009188 CMS
Amneal Pharmaceuticals LLC $22.6105/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139190448 CMS
Lilly USA, LLC $13.9605/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135372718 CMS
ABBVIE INC. $16.0005/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104009184 CMS
Novartis Pharmaceuticals Corporation $19.3505/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087020444 CMS
Neurocrine Biosciences, Inc. $25.7005/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150838036 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $449.94 22
PY2020 $52.37 3
PY2021 $324.58 17
PY2022 $3,172.07 175
PY2023 $5,929.44 320
PY2024 $18,476.30 244
PY2025 $4,442.59 225

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $417,629.90 36
PY2024 Principal investigator $606,667.56 25
PY2023 Principal investigator $4,742.20 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

36 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 TG Therapeutics, Inc. $5,895.00 11/30/2025 Non-covered Recipient Entity
Arizona Neuroscience Research, LLC.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200239
Principal investigator 1 Genentech, Inc. $2,748.00 11/25/2025 Non-covered Recipient Entity
ARIZONA NEUROSCIENCE RESEARCH LLC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211573431
Principal investigator 1 TG Therapeutics, Inc. $2,470.00 11/01/2025 Non-covered Recipient Entity
Arizona Neuroscience Research, LLC.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200237
Principal investigator 1 SK Life Science, Inc. $500.00 10/08/2025 Non-covered Recipient Entity
ARIZONA NEUROSCIENCE RESEARCH
YKP3089C049 No dispute reported 06/30/2026 1252275847
Principal investigator 1 SK Life Science, Inc. $2,000.00 10/08/2025 Non-covered Recipient Entity
ARIZONA NEUROSCIENCE RESEARCH
YKP3089C049 No dispute reported 06/30/2026 1252275849
Principal investigator 1 SK Life Science, Inc. $17,750.00 10/08/2025 Non-covered Recipient Entity
ARIZONA NEUROSCIENCE RESEARCH
YKP3089C049 No dispute reported 06/30/2026 1252275851
Principal investigator 1 TG Therapeutics, Inc. $2,470.00 09/30/2025 Non-covered Recipient Entity
Arizona Neuroscience Research, LLC.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200209
Principal investigator 1 Genentech, Inc. $9,198.90 09/19/2025 Non-covered Recipient Entity
ARIZONA NEUROSCIENCE RESEARCH LLC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211573274
Principal investigator 1 GENZYME CORPORATION $27,218.00 09/03/2025 Non-covered Recipient Entity
Arizona Neuroscience Research Llc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226116749
Principal investigator 1 Genentech, Inc. $2,389.00 08/21/2025 Non-covered Recipient Entity
ARIZONA NEUROSCIENCE RESEARCH LLC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211573427
Principal investigator 1 SK Life Science, Inc. $1,417.60 08/15/2025 Non-covered Recipient Entity
ARIZONA NEUROSCIENCE RESEARCH
YKP3089C049 No dispute reported 06/30/2026 1252275837
Principal investigator 1 Genentech, Inc. $103.00 07/11/2025 Non-covered Recipient Entity
ARIZONA NEUROSCIENCE RESEARCH LLC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211573286
Principal investigator 1 Genentech, Inc. $1,020.40 07/11/2025 Non-covered Recipient Entity
ARIZONA NEUROSCIENCE RESEARCH LLC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211573293
Principal investigator 1 Genentech, Inc. $56.00 07/09/2025 Non-covered Recipient Entity
ARIZONA NEUROSCIENCE RESEARCH LLC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211573283
Principal investigator 1 Genentech, Inc. $6,826.00 07/09/2025 Non-covered Recipient Entity
ARIZONA NEUROSCIENCE RESEARCH LLC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211573289
Principal investigator 1 Genentech, Inc. $103.00 07/01/2025 Non-covered Recipient Entity
ARIZONA NEUROSCIENCE RESEARCH LLC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211573269
Principal investigator 1 Genentech, Inc. $16,960.60 07/01/2025 Non-covered Recipient Entity
ARIZONA NEUROSCIENCE RESEARCH LLC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211573278
Principal investigator 1 SK Life Science, Inc. $1,417.60 06/18/2025 Non-covered Recipient Entity
ARIZONA NEUROSCIENCE RESEARCH
YKP3089C049 No dispute reported 06/30/2026 1252275791
Principal investigator 1 TG Therapeutics, Inc. $8,240.00 06/01/2025 Non-covered Recipient Entity
Arizona Neuroscience Research, LLC.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200173
Principal investigator 1 Genentech, Inc. $13,409.59 05/28/2025 Non-covered Recipient Entity
ARIZONA NEUROSCIENCE RESEARCH LLC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211573419
Principal investigator 1 SK Life Science, Inc. $2,417.70 05/23/2025 Non-covered Recipient Entity
ARIZONA NEUROSCIENCE RESEARCH
YKP3089C049 No dispute reported 06/30/2026 1252275789
Principal investigator 1 Novartis Pharmaceuticals Corporation $54,002.67 05/22/2025 Non-covered Recipient Entity
ARIZONA NEUROSCIENCE RESEARCH
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190312069
Principal investigator 1 Genentech, Inc. $2,689.00 05/21/2025 Non-covered Recipient Entity
ARIZONA NEUROSCIENCE RESEARCH LLC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211573415
Principal investigator 1 TG Therapeutics, Inc. $2,470.00 05/01/2025 Non-covered Recipient Entity
Arizona Neuroscience Research, LLC.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200171
Principal investigator 1 Genentech, Inc. $1,340.00 04/30/2025 Non-covered Recipient Entity
ARIZONA NEUROSCIENCE RESEARCH LLC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211573261
Principal investigator 1 GENZYME CORPORATION $30,505.37 04/21/2025 Non-covered Recipient Entity
Arizona Neuroscience Research Llc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226116732
Principal investigator 1 Genentech, Inc. $7,260.30 04/17/2025 Non-covered Recipient Entity
ARIZONA NEUROSCIENCE RESEARCH LLC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211573265
Principal investigator 1 GENZYME CORPORATION $4,892.00 04/07/2025 Non-covered Recipient Entity
Arizona Neuroscience Research Llc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226116719
Principal investigator 1 Genentech, Inc. $2,389.00 04/02/2025 Non-covered Recipient Entity
ARIZONA NEUROSCIENCE RESEARCH LLC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211573423
Principal investigator 1 TG Therapeutics, Inc. $5,365.76 02/28/2025 Non-covered Recipient Entity
Arizona Neuroscience Research, LLC.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200187
Principal investigator 1 GENZYME CORPORATION $6,209.00 02/24/2025 Non-covered Recipient Entity
Arizona Neuroscience Research Llc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226116711
Principal investigator 1 SK Life Science, Inc. $21,500.00 02/19/2025 Non-covered Recipient Entity
ARIZONA NEUROSCIENCE RESEARCH
YKP3089C049 No dispute reported 06/30/2026 1252275823
Principal investigator 1 TG Therapeutics, Inc. $940.00 02/01/2025 Non-covered Recipient Entity
Arizona Neuroscience Research, LLC.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200169
Principal investigator 1 Novartis Pharmaceuticals Corporation $111,311.16 01/31/2025 Non-covered Recipient Entity
CENTER FOR NEUROLOGY AND SPINE
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190312673
Principal investigator 1 Novartis Pharmaceuticals Corporation $40,145.25 01/07/2025 Non-covered Recipient Entity
HOPE RESEARCH INSTITUTE
AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Nave, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes No dispute reported 06/30/2026 1190304169
Principal investigator 1 TG Therapeutics, Inc. $2,000.00 01/06/2025 Non-covered Recipient Entity
Arizona Neuroscience Research, LLC.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200189